- In April 2025, UCSF launched two clinical trials targeting adenoid cystic carcinoma, including a stereotactic body radiotherapy (SBRT) study for early oligometastatic cases and a REM‑422 trial for recurrent or metastatic disease. These initiatives underscore UCSF’s dedication to expanding non-surgical and advanced treatment options within the Adenoids oncology field
- In March 2025, researchers at the University of Chicago Medical Center identified PRMT5 inhibition as a promising new therapeutic target for adenoid cystic carcinoma. Using AI-driven analysis of gene expression data, they discovered that PRMT5 inhibitors, especially in combination with lenvatinib, significantly reduce tumor growth in preclinical models—highlighting a novel molecular approach in Adenoids cancer treatment
- In August 2024, Chinese researchers at the Children’s Hospital of Soochow University implemented a deep learning model (DenseNet‑121) to automatically detect adenoid hypertrophy from lateral nasopharyngeal X-rays. The model demonstrated AUC values of 0.89–0.87—comparable to senior radiologists—indicating strong potential for AI-assisted pediatric diagnostics
